Boehringer gets FDA's second 'national priority' approval Boehringer Ingelheim's lung cancer drug Hernexeos has become the second medicine approved after an FDA national priority review.

#BoehringerIngelheim has become the second company to get a product approved under the #FDA's #nationalpriorityvoucher programme, claiming the go-ahead for first-line use of #lungcancer drug #Hernexeos.

pharmaphorum.com/news/boehrin...